CR5959A - Tratamiento para la disfuncion sexual femenina - Google Patents

Tratamiento para la disfuncion sexual femenina

Info

Publication number
CR5959A
CR5959A CR5959A CR5959A CR5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A
Authority
CR
Costa Rica
Prior art keywords
apomorphine
treatment
sexual dysfunction
female sexual
clitoris
Prior art date
Application number
CR5959A
Other languages
English (en)
Inventor
El-Rashidy Ragab
Ronsen Bruce
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of CR5959A publication Critical patent/CR5959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA DISFUNSION SEXUAL EN LA MUJER PUEDE SER AMINORADA, SIN EFECTOS SECUNDARIOS SUBSTANCIALES INDESEABLES POR LA ADMINISTRACION SUBLINGUAL DE DOSIS DE APOMORFINA. LA ADMINISTRACION DE APOMORFINA INCREMENTA LA ESTIMULACION DEL CLITORIS MEDIANTE EL FLUJO DE LA SANGRE INTRACAVERNOSAL Y EL FLUJO DE SANGRE EN LAS PAREDES DE LA VAGINA PARA OBTENER LA ERECCION DEL CLITORIS Y EL CONGESTIONAMIENTO VAGINAL DE LA MUJER. LA CONCENTRACION DE PLASMA DE APOMORFINA DE NO MAS DE 5.5 MANOGRAMOS POR MILILITRO ES PREFERIBLEMENTE MANTENIDA.
CR5959A 1998-01-30 1999-01-28 Tratamiento para la disfuncion sexual femenina CR5959A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
CR5959A true CR5959A (es) 1999-07-28

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
CR5959A CR5959A (es) 1998-01-30 1999-01-28 Tratamiento para la disfuncion sexual femenina

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
EP1089736A2 (en) * 1998-06-22 2001-04-11 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20050020547A1 (en) * 1999-11-08 2005-01-27 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
KR20030036157A (ko) * 2000-04-07 2003-05-09 탭 파마슈티칼 프로덕츠 인코포레이티드 아포모르핀 유도체 및 이의 사용 방법
AU6124401A (en) * 2000-05-09 2001-11-20 Nitromed Inc Infrared thermography and methods of use
ATE369868T1 (de) * 2000-06-27 2007-09-15 Qualilife Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung der weiblichen sexuellen reaktion
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
IL155667A0 (en) 2000-11-15 2003-11-23 Tap Pharmaceutical Prod Inc Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
AU2689502A (en) * 2000-11-22 2002-06-03 Abbott Lab The use of selective dopamine d4 receptor agonists for treating sexual dysfunction
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
JP2005526790A (ja) * 2002-03-19 2005-09-08 ミシェル ホリック アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
WO2006105615A1 (en) * 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2007110868A2 (en) 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
US20130210867A1 (en) * 2010-04-15 2013-08-15 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
JPH07506823A (ja) * 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
PL342062A1 (en) 2001-05-21
HN1999000015A (es) 1999-08-23
GT199900013A (es) 2001-07-20
AR017976A1 (es) 2001-10-24
HUP0101268A2 (hu) 2001-09-28
IL137569A0 (en) 2001-07-24
PL194350B1 (pl) 2007-05-31
ZA99686B (en) 1999-07-28
AU752928B2 (en) 2002-10-03
DZ2714A1 (fr) 2003-09-01
SK11362000A3 (sk) 2001-02-12
BR9908038A (pt) 2002-01-02
MXPA00007447A (es) 2006-01-25
MA26600A1 (fr) 2004-12-20
NZ506597A (en) 2003-07-25
NO20003845L (no) 2000-09-28
JP2002501875A (ja) 2002-01-22
HUP0101268A3 (en) 2002-12-28
GC0000096A (en) 2005-06-29
WO1999038467A1 (en) 1999-08-05
PA8467801A1 (es) 2000-09-29
NO20003845D0 (no) 2000-07-27
IL137569A (en) 2006-08-01
CA2322289A1 (en) 1999-08-05
EP1056419A1 (en) 2000-12-06
HK1040901A1 (en) 2002-06-28
BG64667B1 (bg) 2005-11-30
NO319821B1 (no) 2005-09-19
TW550069B (en) 2003-09-01
CN1313742A (zh) 2001-09-19
EP1056419A4 (en) 2007-05-02
US5945117A (en) 1999-08-31
TNSN99008A1 (fr) 2005-11-10
US6193992B1 (en) 2001-02-27
TR200002220T2 (tr) 2000-12-21
CO4970819A1 (es) 2000-11-07
UY25374A1 (es) 1999-09-27
JO2085B1 (en) 2000-05-21
KR20010040477A (ko) 2001-05-15
BG104715A (bg) 2001-02-28
CN1250221C (zh) 2006-04-12
AU2564499A (en) 1999-08-16
PE20000240A1 (es) 2000-03-31
HK1040901B (zh) 2006-11-24

Similar Documents

Publication Publication Date Title
PA8467801A1 (es) Tratamiento de disfuncion sexual femenina
EP1253929A4 (en) USE OF RELAXIN FOR THE TREATMENT OF DISEASES CONTAINED BY VASCARIAL CONSTRUCTION
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
US5891915A (en) Method for enhancing female sexual response and an ointment therefor
EA199700213A1 (ru) Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
NO20021035D0 (no) Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
ATE289293T1 (de) Substituierte aminoalkylamid-derivate als antagonisten des follikel-stimulierenden hormons
RU2002104498A (ru) Применение тозилхлорамидов для лечения заболеваний кожи, слизистой оболочки, органов и тканей
US20080213407A1 (en) Topical application of L-arginine and menthol to increase penis size
AR019694A1 (es) Metodo para el tratamiento o reduccion de la disfuncion sexual femenina.
ES2042818T3 (es) Agente terapeutico para la trombocitopenia.
ECSP992843A (es) Procedimiento para aminorar la disfuncion sexual femenina
RU2224562C2 (ru) Способ лечения хронического простатита
RU2188675C2 (ru) Способ лечения больных с аменореей центрального генеза
KR20010076961A (ko) 성기능장애 예방 및 치료용 약제
RU94031913A (ru) Способ лечения хронического кандидозного вульвовагинита
TH65931A3 (th) ยาสำหรับหญิงที่เสื่อมสมรรถภาพทางเพศและวิธีการใช้
RU2529812C2 (ru) Биологически активная композиция
محمد أكرم رنداوا et al. A Review of the Developmental, Structural, Biochemical, Pathophysiological and Pharmacological Similarities between Male and Female Genitals
MXPA02001219A (es) Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
RU95101168A (ru) Способ формирования желаемого пола зарождаемого ребенка
Korda et al. THE FEMALE PROSTATE AND FEMALE EJACULATION IS KNOWN SINCE THE 11TH CENTURY: 1096
TH65931A (th) ยาสำหรับหญิงที่เสื่อมสมรรถภาพทางเพศและวิธีการใช้

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)